• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Genprex Inc. (Amendment)

    2/14/24 2:14:47 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNPX alert in real time by email
    SC 13G/A 1 tm244732d15_sc13ga.htm SC 13G/A

     

    CUSIP No: 372446104

     

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Genprex, Inc.
    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    372446104
    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 372446104

     

    (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc. 

     
    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     
        (a)   ¨
    (b)   ¨
    (3)

    SEC USE ONLY

     

     
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands 

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING

    PERSON WITH

    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER **

     

    3,089,092

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER **

     

    3,089,092

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,089,092

     
    (10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     
           ¨
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.9% 

     
    (12)

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO 

     

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 372446104

     

    (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc. 

     
    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     
        (a)   ¨
    (b)   ¨
    (3)

    SEC USE ONLY

     

     
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING

    PERSON WITH

    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER **

     

    3,089,092

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER **

     

    3,089,092

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,089,092

     
    (10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     
           ¨
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.9% 

     
    (12)

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO 

     

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 372446104

     

    Item 1.

     

    (a)Name of Issuer

     

    Genprex, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    3300 Bee Cave Road, #650-227, Austin, TX 78746

     

    Item 2(a).Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)Title of Class of Securities

     

    Common stock, $0.001 par value per share

     

    Item 2(e)CUSIP Number

     

    372446104

     

     

     

     

    CUSIP No: 372446104

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)  ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
         
    (b)  ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c)  ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d)  ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e)  ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f)  ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g)  ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h)  ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)  ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j)  ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k)  ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of (i) 618,256 Shares, and (ii) Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%.

     

    The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023 indicates there were 59,434,822 Shares outstanding as of November 6, 2023.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 372446104

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 372446104

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 12, 2024

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         

    By: Heights Capital Management, Inc. pursuant to a Limited Power of Attorney, a copy of which was previously filed

      By: /s/  Brian Sopinsky
      Name: Brian Sopinsky
      Title:  Secretary

     

    By: /s/  Brian Sopinsky    
    Name: Brian Sopinsky    
    Title: Secretary    

     

     

     

     

    CUSIP No: 372446104

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*

     

    *Previously Filed

     

     

    Get the next $GNPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

      Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,

      5/13/24 8:31:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

      Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy

      8/22/23 7:30:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    SEC Filings

    See more
    • SEC Form S-1 filed by Genprex Inc.

      S-1 - Genprex, Inc. (0001595248) (Filer)

      5/14/25 8:51:24 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Genprex Inc.

      10-Q - Genprex, Inc. (0001595248) (Filer)

      5/12/25 4:31:16 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Genprex, Inc. (0001595248) (Filer)

      5/7/25 7:30:09 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • National Securities initiated coverage on Genprex with a new price target

      National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00

      1/26/21 7:48:53 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 585 shares, decreasing direct ownership by 3% to 22,471 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      2/19/25 8:01:36 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO and CFO Confer Ryan M. covered exercise/tax liability with 395 shares, decreasing direct ownership by 1% to 38,743 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      2/19/25 8:00:01 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Moreno Toscano Jose Antonio was granted 4,750 shares, increasing direct ownership by 153% to 7,845 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      12/6/24 5:55:11 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Genprex Inc.

      SC 13G/A - Genprex, Inc. (0001595248) (Subject)

      10/24/24 12:23:37 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genprex Inc.

      SC 13G - Genprex, Inc. (0001595248) (Subject)

      10/22/24 12:01:59 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genprex Inc.

      SC 13G - Genprex, Inc. (0001595248) (Subject)

      10/3/24 10:09:50 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

      Presentation to Highlight Genprex's Study of Reqorsa® Gene Therapy in Combination with Tecentriq® for the Treatment of Extensive Stage Small Cell Lung Cancer AUSTIN, Texas, May 29, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has been selected to present at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois and online. Ge

      5/29/25 7:00:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

      Novel Gene Therapy is Addressing Both Type 1 and Type 2 Diabetes AUSTIN, Texas, May 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research collaborators presented positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, in an oral presentation at the American Society of Gene and Cell Therapy's (ASGCT) 28th Annual Meeting which took place May 13-17, 2025 in New Orleans, Louisiana.

      5/28/25 7:00:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

      Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education AUSTIN, Texas, May 7, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that following the recent completion of its two-year Sponsored Research Agreement (SRA) with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt) to study Type 1 diabetes (T1D) and Type 2 diabetes (T2D), the parties have entered into a new SRA to study GPX-002, the Company's gene therapy for diabetes, in T1

      5/7/25 7:00:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care